Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 12/20 | 0.43 |
| ▸ | TK1 | P04183 | 2/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8076819 | 0.79 | PNP (0.68) | PNPXDH | |
| SCHEMBL24499105 | 0.71 | PNP (0.46) | PNPTK1XDHHBB | |
| SCHEMBL786949 | 0.68 | NPSR1 (0.50) | NPSR1PNPTK1HBBHSD17B10 | |
| SCHEMBL18870774 | 0.68 | PNP (0.49) | PNPTK1XDH | |
| SCHEMBL4856569 | 0.68 | NPSR1 (0.30) | NPSR1 | |
| SCHEMBL10169133 | 0.67 | NPSR1 (0.66) | NPSR1PNPTSHR | |
| SCHEMBL13587333 | 0.67 | PNP (0.48) | PNPTK1XDH | |
| SCHEMBL669006 | 0.67 | TK1 (0.68) | PNPTK1USP2TSHREDNRA | |
| SCHEMBL12956833 | 0.66 | NPSR1 (0.70) | NPSR1PNPTSHRHBB | |
| SCHEMBL18870637 | 0.66 | PNP (0.53) | PNPTK1XDHHPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-7795270-B2 | DUTPase inhibitors | MEDIVIR AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080312183-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1701727-A1 | DUTPASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005065689-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312183-A1 | Dutpase Inhibitors | DUT, DHODH, RNASEH1 | NPSR1 2924/4885PNP 31/4885TK1 75/4885 |
| US-20110021459-A1 | DUTPASE INHIBITORS | DUT, DHODH, NAT10 | NPSR1 3435/4885PNP 41/4885TK1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.